As previously reported, Guggenheim downgraded Travere Therapeutics to Neutral from Buy with no price target. The firm lowered it estimates for Travere’s Filspari and downgraded shares given the smaller role the firm expects Filspari to have in the IgA nephropathy, or IgAN, treatment space once multiple APRIL/BAFF inhibitors enter the U.S. market in the 2026 timeframe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics submits sNDA for FILSPARI for IgAN
- Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
- Travere Therapeutics to Present at Upcoming Investor Conferences
- Travere’s Sparsentan Nears European Market Breakthrough
